JCO Oncology Practice 2021 September 7 [Link] Anna K Nowak, Alannah Jackson, Calvin Sidhu Abstract The management of pleural mesothelioma has changed with the demonstration that first-line checkpoint blockade therapy improves survival. This review covers issues of relevance to the practicing medical oncologist, with an emphasis on the palliative setting and on new information. Until…

Read More

Cancer Treatment and Research Communications 2021 February 24 [Link] Xiaomin Niu, Chenglei Zhou, Aiyan Hu, Lingzi Su, Dan Lin, Hui Han, Yan Lu Abstract Synchronous malignant mesothelioma (MM) and lung carcinoma are extremely rare in patients without a history of asbestos exposure and poses tremendous difficulties in clinical management. We report a patient without asbestos…

Read More

Lancet 2021 January 21 [Link] Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman Abstract Background: Approved systemic treatments…

Read More

Frontiers in Oncology 2020 November 13 [Link] Olivia Lauk, Karina Bruestle, Thomas Neuer, Bianca Battilana, Thi Dan Linh Nguyen, Thomas Frauenfelder, Rolf Stahel, Walter Weder, Alessandra Curioni-Fontecedro, Isabelle Opitz Abstract Objectives: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to platinum-based chemotherapy/pemetrexed in 1st line treatment of advanced malignant pleural mesothelioma (MPM), significantly improved overall…

Read More

The Lancet Oncology 2020 September [Link] Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook, Nick Pavlakis, Karen Briscoe, Kenneth J O’Byrne, Christos S Karapetis, Wei-Sen Lam, Ailsa Langford, Sonia Yip, Martin R Stockler Abstract Background: There is…

Read More

Clinical Lung Cancer 2020 July 3 [Link] Arkadiusz Z Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E Vokes, Hedy L Kindler Abstract Background: The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of…

Read More

Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported…

Read More

Clinical Lung Cancer 2019 September 5 [Link] Franceschini D, De Rose F, Cozzi S, Renna I, Franzese C, Di Brina L, Navarria P, D’Agostino GR, Mancosu P, Tomatis S, Scorsetti M Abstract INTRODUCTION: We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM)…

Read More

Oncotarget 2018 April 27 [Link] Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a biologically highly aggressive tumor arising from the pleura with a…

Read More

European Journal of of Radiology [2017 January] [Link] Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T Abstract PURPOSE: Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most…

Read More